Business

Know the Business — Molina (MOH)

What kind of business is Molina, what should it trade like, and what has to be true for FY2026 numbers to compound back to where the franchise can earn?

Molina is a disciplined, low-cost, low-margin, state-contract Medicaid operator with bolt-on duals and Marketplace optionality. Its quality is operational, not structural — the moat is RFP win rate, member-acquisition cost on dual-eligibles, and a parent/subsidiary capital architecture that lets a small balance sheet finance a much larger book — not pricing power, brand, or scale. So it should be valued through the cycle, not at one snapshot — and FY2025 was the most violent snapshot in the data.

1. The Verdict in One Page

The KPI strip is the headline of a cycle bottom, not the franchise. FY2025 revenue hit \$45.4 billion at a 91.7% consolidated MCR; net income fell to \$472 million from \$1,179 million the year prior, and diluted EPS dropped to \$8.92 from \$20.42 [1]. Returns on equity collapsed from a steady 25-32% in FY2020-24 to 11.6% in FY2025 — not because the business broke, but because medical cost trend ran roughly 7.5% against actuarial rates priced for ~4.5% [2] [3]. Reading the FY2025 P\&L as the run rate gets the company wrong in both directions.

2. The Economic Engine — A PMPM Spread Business Running on \$0.92 of Every Premium Dollar

Strip away the segments and the engine is one equation. A state Medicaid agency or CMS pays Molina a per-member-per-month ("PMPM") rate; Molina absorbs medical and administrative cost risk for that population in exchange [4]. The contract is fixed in price, variable in cost, and the gap is the company's earnings.

The unit economics: about \$0.92 of every dollar of premium revenue is medical care cost [5]; after another \$0.065 of G\&A and a couple of pennies of D\&A, interest, and tax [5], the company keeps about a penny of net income on a dollar of revenue. Said differently: a single point of MCR overshoot wipes out a meaningful fraction of operating income. Molina spells this sensitivity out in its own 10-K: had FY2025 MCR been 92.7% rather than 91.7%, diluted EPS would have been roughly \$2.72 instead of \$8.92 — a \$6.20 difference from 100 basis points [6].

That sensitivity is the central economic fact about Molina. Everything else — the segments, the moat conversation, the buyback program, even the multi-year multi-billion-dollar M\&A pipeline — is downstream of how well management can keep that 92¢ line steady against a continuously-trending medical cost base while states reset price once a year.

How the engine scales

The other side of the operating leverage equation is G\&A — what Molina calls its "low-cost operator" claim [7]. The G\&A ratio is the cleanest visible evidence of operating discipline:

G\&A has compressed from 7.6% in FY2020 to 6.5% in FY2025 — 110 basis points of leverage over five years on a revenue base that nearly tripled from \$19.4 billion to \$45.4 billion. That is real evidence that the back office scales. The flipside: G\&A leverage is small comfort when 92 cents of every dollar is medical cost and rates lag trend.

3. The Three Programs — Three Different Businesses Inside One Ticker

Molina reports four segments — Medicaid, Medicare, Marketplace, Other — but the first three do all the work [8]. Each is structurally different: different customers, different price-setting cadence, different competitive set, different acuity profile. Treating them as one model is the most common modelling mistake new investors make.

Segment shapes for FY2025: Medicaid is roughly 75% of premium revenue at 4.57 million members [9] [8]; Medicare ~14% on 262 thousand higher-acuity members [10]; Marketplace ~10% on 655 thousand members after a +252,000 net add year [10]; "Other" is rounding (the ConnectiCare commercial book plus LTSS consulting in Wisconsin [8]).

Medicaid is the company

Medicaid MCR ran 87-89% from FY2020 through FY2023 — the 88-89% long-term target range management still anchors guidance against [3] — then climbed 150 basis points in FY2024 and another 150 basis points in FY2025 to 91.8% [11]. The medical margin in absolute dollars actually fell from \$2,979 million in FY2024 to \$2,652 million in FY2025 even as premium revenue grew 5% — a clean statement that 2025 was a rate-versus-trend year, not a volume problem. Management's full-year FY2026 Medicaid MCR guide is 92.9%, built on a 4% rate increase against an expected 5% medical cost trend, with the optionality of off-cycle and retrospective rate updates from states later in the year [2].

Medicaid is also where the structural growth case lives. Management has set a long-term 11-13% premium revenue growth target and expects to surpass \$50 billion of premium revenue in 2027 [7]. The fuel is a mix of RFP wins, footprint expansion (Idaho, Florida Kids, Mississippi, Nevada, Massachusetts), and bolt-on M\&A — the same engine that delivered the prior decade of growth.

Medicare is being reshaped — exit MAPD, double down on duals

The Medicare story for FY2025 is a deliberate strategic narrowing. In February 2026, Molina announced it will exit Medicare Advantage-Part D ("MAPD") for plan year 2027 because it "does not align with our strategic shift to focus exclusively on dual eligible members" — MAPD represented approximately 117,000 members and \$1,566 million, or 25% of FY2025 Medicare segment premium revenue [12]. The replacement is a fast-growing dual-eligible book of D-SNP, HIDE, FIDE, and the converted MMP contracts that crossed over on January 1, 2026 in Illinois, Michigan, Ohio, South Carolina, and Texas, totaling \$1.9 billion of revenue [13].

Why concentrate on duals? Because duals are the one product where Molina's Medicaid book is a structural competitive advantage. A dual-eligible member is already a Molina Medicaid member — Molina knows the provider network, the social determinants, the care plan; member-acquisition cost is much lower than for a pure Medicare Advantage shopper that CVS/Aetna, Humana, or UnitedHealth would compete for. Q1 FY2026: the converted HIDE/FIDE members on \$2 billion of revenue "performed much better out of the gate than we had anticipated" [14], reinforcing the thesis.

Marketplace is volatile and is being deliberately shrunk

Marketplace MCR jumped from 75.4% in FY2024 to 90.6% in FY2025 — a 1,520-basis-point single-year reset [10]. The cause was a textbook adverse-selection event: Molina added 252,000 net members in 2025 [10], but the new mix was higher-acuity than priced, and CMS program-integrity initiatives disenrolled lower-acuity members whose accumulated claims Molina still owed. Q4 FY2025 Marketplace MCR ran at 99%.

Management's response is rare for the industry — explicitly shrink the segment to defend margin. FY2026 guidance puts year-end Marketplace membership at approximately 220-250 thousand, down from 655 thousand at end-2025, a roughly 50% premium revenue cut [12] [2]. The renewal rate of remaining members is now 70%, concentrated in the silver tier (50% of mix) [2], and Q1 FY2026 reported MCR of 84% — or 79.5% adjusted for prior-year risk adjustment and program integrity impacts [15]. This is a deliberate exit from competition for low-income, subsidy-driven members where Centene's Ambetter (5.5 million Marketplace members at end-2025 [16]) is the structural low-cost incumbent.

4. Returns on Capital — High at the Top of the Cycle, Crushed at the Bottom

This is a thin-margin, asset-light operator: total assets of \$15.6 billion at year-end FY2025 produce \$45.4 billion of revenue, an asset turnover near 2.9x — the highest in the peer set. Combined with operating margins that have ranged from 1.7% (FY2025 trough) to 6.0% (FY2019 peak), ROE swings violently with the cycle.

The seven-year average ROE through FY2025 is roughly 26%, ROCE roughly 21%. FY2025 cuts both in half. The honest framing: if FY2024 MCR-of-89.1% conditions repeat in FY2026-27 (management's central case in the Q1 transcript is for trend at 5% and rates at 4%, with off-cycle catch-up upside [2]), ROE returns to the 20-25% zone within two years. If trend remains 7-8% and rates remain at 4%, FY2026 looks much like FY2025. The reader's view on the rate-vs-trend gap is the dominant variable for ROE over the next two years.

5. Moat Analysis — A Scorecard Without Self-Congratulation

The right way to read Molina's competitive position is to drop the word "moat" and replace it with the four mechanical advantages that actually show up in the filings. Most of these are real, but they are operating-cost moats, not pricing moats.

A few of those rows need direct citation since they carry the moat verdict:

• The procurement track record is management's own quantification: 90% re-procurement win rate on \$14 billion of retained revenue and an 80% new-contract win rate worth \$20 billion in premium since 2019, alongside acquisitions totaling more than \$10 billion of revenue over the same period [7]. FY2025 alone added "nearly \$9 billion of incremental annual premium revenue" from RFP wins and the ConnectiCare acquisition [18], and the FY2026 award stack includes the Florida CMS Kids contract (sole-selected, ~120,000 enrollees [19]; ~\$6 billion run-rate revenue per management [20]).
• The auto-assignment mechanic is what converts low-cost into bid wins: state auto-assignment algorithms explicitly include "plans with the lowest bid in a county or region" among the criteria for assigning Medicaid members who do not choose a plan [4]. That is the literal economic mechanism connecting G\&A leverage to membership growth.
• The dual-eligible angle: Molina explicitly named the exit of MAPD and the focus on duals as the strategic shift [12], and the early Q1 FY2026 read on the HIDE/FIDE conversion was that "they performed much better out of the gate than we had anticipated" [14].
• The pricing-power constraint is structural: Medicaid PMPM rates are set annually by states subject to federal actuarial-soundness standards [4], and incumbency does not guarantee contract retention — "Incumbency status may not necessarily guarantee our ability to retain contracts when they are up for rebidding" [21]. Virginia, where Molina lost the Cardinal Care Managed Care 2.0 procurement in 2024 and saw its DMAS contracts terminate effective June 30, 2025, is the most recent reminder [19].

6. State Concentration — The Anchor Four, the Procurement Risk

Each of California, New York, Texas, and Washington accounted for approximately 10% or more of consolidated Medicaid premium revenue in FY2025: Texas \$5,735 million (18%), California \$4,170 million (13%), Washington \$4,194 million (13%), and New York \$3,221 million (10%) [9] [22]. Together those four states are roughly 54% of Medicaid premium revenue and about 40% of total company revenue.

The procurement cadence shows what is at risk and when:

• California Medi-Cal contracts effective January 1, 2024 cover four counties (Los Angeles, Riverside/San Bernardino, Sacramento, San Diego) [9] — a multi-year stable book.
• Texas STAR+PLUS commenced September 1, 2024, with the STAR and CHIP contract still pending final terms [22]. Largest single concentration; biggest single procurement risk.
• Washington Apple Health was renewed through 2026 and expected through 2027, with an RFP no earlier than Q4 2026 and an expected contract effective date of January 1, 2028 [22]. This is the next known procurement risk to watch.
• New York is multi-county; about 10% of Medicaid premium [9].

The 10-K is explicit about what a procurement loss means: "A loss of any of our significant Medicaid contracts could have a material adverse effect on our business, financial condition, cash flows, or results of operations" [9]. Virginia in 2024 was the most recent worked example.

7. Capital Allocation — A Plumbing System, Not a Capital Allocator's Showcase

Molina does not raise outside equity. The capital-allocation playbook is a regulated plumbing system: medical margin earned at the health-plan subsidiary level → statutory capital cushion maintained at the subsidiary → excess upstreamed to the parent via state-regulator-approved dividends → at the parent, used for debt service, M\&A, and buybacks. The parent itself runs lean.

The flow, in plain English:

• Subsidiary dividends to parent: regulated health plan subsidiaries paid \$985 million to the parent in 2025 (\$997 million in 2024) [23]. The parent contributed \$439 million back into subsidiaries (mainly Connecticut, California, Mississippi) to satisfy statutory capital requirements [23]. Net upstream of roughly \$546 million is what funded everything else.
• Buybacks at the cycle: FY2025 buybacks totalled \$1 billion — Molina purchased ~1.68 million shares for \$500 million in Q1 2025 at an average cost of \$297.83 per share, and ~2.85 million shares for \$500 million in Q3 2025 at \$175.50 per share [19]. The Q3 program was authorized in April 2025 for up to \$1 billion through December 31, 2026 [24]. The 41% gap between the two average prices is what you'd want to see from a disciplined repurchaser through a cycle reset — buying more shares at a lower price.
• Debt is cheap and laddered: In November 2025, Molina issued \$850 million of 6.500% Senior Notes due 2031, using the proceeds to retire \$740 million of existing term loan debt; the weighted-average cost of fixed debt sits at 5.0% [24] and the new revolving facility provides \$1.25 billion of capacity through November 2030, plus an additional \$800 million of incremental term-loan capacity available specifically to finance acquisitions [25].
• M\&A discipline: In the Q1 FY2026 call, CEO Joe Zubretsky framed the M\&A pipeline as "full of actionable opportunities," with the historical pricing benchmark of "22 to 23 percent of revenue" now giving way to a book-value benchmark because so many distressed sellers are priced near regulatory-capital floors — "If you're only paying for regulatory capital, an M\&A deal can be as good as, if not better than, a new contract win" [26]. For a regulated business where every acquired plan brings statutory capital with it, this is the right frame; whether the discipline holds when sellers' capital is permanently impaired is the right question to test in the next twelve months.

8. Track Record — Promises and Results, 2020-2025

The best test of management quality in a cyclical, contract-driven business is the consistency between what was promised and what was delivered. Molina's six-year record shows a high-quality operator who has over-delivered on the things it controls (G\&A, RFPs, M\&A integration) and under-delivered when forces it does not control (medical cost trend, redetermination acuity, Marketplace mix) collided with the annual rate-reset cycle.

The CEO's framing on the Q1 FY2026 call captures the management mindset: "We will again realize the intrinsic value of the franchise we have built over the past 8 years" [2] — a reminder that current CEO Joe Zubretsky was hired in 2017 as a turnaround CEO and that the FY2018 swing from a \$512 million net loss to a \$707 million net profit was the inflection. The investor should weight this management team's history of execution heavily against the apparent damage to FY2025 numbers — but should also keep in mind that the most powerful execution lever (procurement RFP wins) does not solve a within-contract medical-trend overshoot. The two skills are separable.

9. Embedded Earnings — The Mechanic of the FY2027 Bridge

Molina uses an unusual but useful disclosure called embedded earnings: the future incremental contribution of new contract wins and acquisitions that have not yet hit the run-rate P\&L. For FY2026, management quantifies \$2.50 per share of embedded earnings as the combination of (a) the MAPD product losses being eliminated in 2027 and (b) the Florida CMS Kids first-year implementation costs that ramp into a profitable run rate in 2027 [15]. Both are mechanical — one is a planned exit, one is an implementation lift.

Per CFO Mark Keim: "Both are certain to be positive impacts to our 2027 performance." [15] Per CEO Zubretsky on the MAPD drag: it produced roughly \$1 per share of FY2026 earnings drag that won't repeat [14].

The illustration above puts FY2027 baseline EPS at roughly \$7.50 — before any Medicaid rate catch-up. The math is mechanical from management's own disclosed components; the rate-vs-trend gap closing further is upside. The reader should verify the bridge with the Investor Day disclosure (scheduled May 8, 2026) [2], but the conceptual framework is the right one: FY2025 is the snapshot, FY2027 is the franchise.

10. Peer Set — Centene Is the Only Like-for-Like Comp

A reminder, because the auto-screened peer set in this run includes UnitedHealth, CVS, Cigna, Elevance, Humana, and Centene — only one of those is a true business-model match.

The Centene comparison matters because FY2025 was the industry margin reset year, and Centene's record clarifies that this was not a Molina-specific failure: Centene's adjusted diluted EPS fell from \$7.17 in FY2024 to \$2.08 in FY2025 [29], and Centene took a \$6.7 billion goodwill impairment that drove a GAAP net loss [29]. Centene serves 27.6 million members and is described in its own filing as the "nation's largest managed care company focused on underserved populations" [30]. Molina is a quarter of Centene's size and roughly the same business — and Molina took no impairment. That is a non-trivial relative data point on portfolio quality and acquisition discipline.

11. The Valuation Lens — How to Underwrite This Stock

Three observations frame how the right buy-side investor should approach Molina's valuation:

1. Don't use FY2025 P/E. EPS is at a cycle bottom. A 12x P/E off \$8.92 looks cheap by absolute standards but is being struck off depressed numerators. Off the management-guided FY2026 floor of "at least \$5," even modest multiples imply a premium. Neither single-year framing is the right one.
2. Do use through-cycle EPS or the FY2027 embedded-earnings bridge. Through-cycle ROE has averaged 24-25% on book value of about \$77 per share at end-FY2025 (\$4,069 million equity divided by roughly 52.9 million shares). That implies through-cycle EPS in the high teens. The FY2027 embedded bridge of roughly \$7.50 illustrated above is the starting point before rate catch-up, not the destination.
3. Watch parent-cash conversion and the buyback discipline. A 1-for-1 conversion of parent net retained cash into buybacks at the right prices (FY2025 cycle-trough buybacks at \$175.50 in Q3) is materially more accretive than maintaining the cash on balance sheet. Continued discipline at sub-cycle prices is a positive signal; chasing the price up to multi-hundred dollars again is a negative one.

12. What Has to Be True

Five things have to be true for the Molina franchise to compound back to its through-cycle earnings power over the next 24 months:

1. Medicaid rate-vs-trend gap closes. Management's FY2026 build is 4% rate against 5% trend; off-cycle catch-up rate filings are the swing factor [2]. The Q1 FY2026 result of 92% Medicaid MCR with "modestly favorable" trend [2] is the first positive data point. Two more quarters of confirmation, and consensus FY2027 EPS rerates.
2. OBBBA implementation comes in at the company's 15-20% expectation, not above. Molina has framed the membership impact as 15-20% reduction on 1.2 million Medicaid Expansion members by 2029 [18] [31]. State implementations are still being designed; the actual figure depends on how states design work-requirement and redetermination cadences.
3. Marketplace shrinkage stops bleeding into adjacent KPIs. Cutting the book in half is a margin-defense move; the test is whether it actually restores normalized 80% MCR for the residual book without dragging Medicare or Medicaid acuity mixes.
4. The procurement engine keeps producing. The "near \$9 billion of incremental annual premium revenue" delivered in 2025 [18] was an exceptional vintage. The base rate of RFP wins matters more than any single year — Texas STAR/CHIP and Washington Apple Health 2028 are the next material decisions.
5. M\&A discipline at book-value-anchored prices. With \$1.25 billion of revolver capacity plus \$800 million of acquisition-financing incremental term-loan capacity [25] and a willingness of distressed sellers to transact at book, this is an environment where the company can lay out the next decade of growth at attractive prices — or destroy that optionality with one bad deal.

References

1. Molina Healthcare, Inc. — FY2025 Annual Report (Form 10-K), Item 7 MD\&A, Consolidated Results — p.78
2. Molina Healthcare, Inc. — Q1 FY2026 Earnings Call Transcript, CEO Prepared Remarks — p.1
3. Molina Healthcare, Inc. — Q4 FY2024 Earnings Call Transcript, Q\&A on FY2025 Medicaid MCR build and long-term range — p.6
4. Molina Healthcare, Inc. — FY2025 Annual Report (Form 10-K), Item 1 Business, Medicaid Basis for Premium Rates / Member Enrollment — p.17
5. Molina Healthcare, Inc. — FY2025 Annual Report (Form 10-K), Item 7 MD\&A, Financial Results / MCR / G\&A — p.78
6. Molina Healthcare, Inc. — FY2025 Annual Report (Form 10-K), Item 1A Risk Factors, MCR sensitivity / 100bp scenario — p.41
7. Molina Healthcare, Inc. — FY2025 Annual Report (Form 10-K), Item 1 Business, Vision / Strategy / Retrospective — p.9
8. Molina Healthcare, Inc. — FY2025 Annual Report (Form 10-K), Item 1 Business, Our Segments / Segment Membership and Premium Revenue — p.9
9. Molina Healthcare, Inc. — FY2025 Annual Report (Form 10-K), Item 1 Business, Status of Significant Contracts (California, NY, FMAP, 75% Medicaid) — p.15
10. Molina Healthcare, Inc. — FY2025 Annual Report (Form 10-K), Item 7 MD\&A, Segment Performance — Medicare and Marketplace — p.84
11. Molina Healthcare, Inc. — FY2025 Annual Report (Form 10-K), Item 7 MD\&A, Segment Performance — Medicaid — p.82
12. Molina Healthcare, Inc. — FY2025 Annual Report (Form 10-K), Item 1 Business, MAPD Exit / Marketplace overlap — p.21
13. Molina Healthcare, Inc. — FY2025 Annual Report (Form 10-K), Item 1 Business, Status of MMP Contracts / MMP to D-SNP transition — p.19
14. Molina Healthcare, Inc. — Q1 FY2026 Earnings Call Transcript, Medicare segment / MAPD drag / HIDE FIDE — p.8
15. Molina Healthcare, Inc. — Q1 FY2026 Earnings Call Transcript, CFO Prepared Remarks / Embedded earnings / Marketplace MCR adj — p.2
16. Centene Corporation — FY2025 Annual Report (Form 10-K), Item 1 Business, Commercial / Marketplace (Ambetter 5.5M) — p.18
17. Molina Healthcare, Inc. — FY2025 Annual Report (Form 10-K), Item 1 Business, ACA / enhanced PTC expiration / Marketplace Integrity Rule — p.25
18. Molina Healthcare, Inc. — FY2025 Annual Report (Form 10-K), Item 1 Business, Key Developments preamble (\$9B incremental premium) / OBBBA — p.11
19. Molina Healthcare, Inc. — FY2025 Annual Report (Form 10-K), Item 1 Business, Key Developments (Florida Kids, ConnectiCare, Virginia) and Capital Management (buybacks) — p.13
20. Molina Healthcare, Inc. — Q1 FY2026 Earnings Call Transcript, Florida CMS Kids \$6B run rate / RBC 305% — p.6
21. Molina Healthcare, Inc. — FY2025 Annual Report (Form 10-K), Item 1 Business, Competitive Conditions and Environment — p.32
22. Molina Healthcare, Inc. — FY2025 Annual Report (Form 10-K), Item 1 Business, Texas / Washington Medicaid contract detail — p.17
23. Molina Healthcare, Inc. — FY2025 Annual Report (Form 10-K), Item 7 MD\&A, Liquidity — Subsidiary dividends \$985M and parent contributions \$439M — p.86
24. Molina Healthcare, Inc. — FY2025 Annual Report (Form 10-K), Item 7 MD\&A, Capital Structure — \$1B buyback authorization / 6.500% Notes due 2031 — p.90
25. Molina Healthcare, Inc. — FY2025 Annual Report (Form 10-K), Item 7 MD\&A, Future Sources — Credit Agreement \$1.25B + \$800M acquisition term-loan capacity — p.92
26. Molina Healthcare, Inc. — Q1 FY2026 Earnings Call Transcript, M\&A pipeline / 22-23% revenue benchmark / book value — p.9
27. Molina Healthcare, Inc. — FY2025 Annual Report (Form 10-K), Item 7 MD\&A, Operating Activities — net cash used \$535M — p.88
28. Molina Healthcare, Inc. — Q1 FY2026 Earnings Call Transcript, Parent cash \$200M to \$600M+ — p.5
29. Centene Corporation — FY2025 Annual Report (Form 10-K), Non-GAAP Financial Presentation — Adjusted EPS \$2.08 vs \$7.17 / goodwill impairment — p.10
30. Centene Corporation — FY2025 Annual Report (Form 10-K), Item 1 Business, Overview / 27.6M members — p.12
31. Molina Healthcare, Inc. — FY2025 Annual Report (Form 10-K), Item 1 Business, Trends and Uncertainties — OBBBA / 1.2M Expansion / 15-20% — p.23